Cart
sales@molnova.com
GSK-LSD1 dihydrochloride
CAS No. 1431368-48-7
GSK-LSD1 dihydrochloride( —— )
Catalog No. M17295 CAS No. 1431368-48-7
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 62 | In Stock |
|
| 10MG | 89 | In Stock |
|
| 25MG | 148 | In Stock |
|
| 50MG | 213 | In Stock |
|
| 100MG | 319 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-LSD1 dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorLSD1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1431368-48-7
-
Formula Weight289.24
-
Molecular FormulaC14H22Cl2N2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESc1ccc(cc1)[C@@H]1C[C@H]1NC1CCNCC1.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Structural Genomics Consortium.
molnova catalog
related products
-
AZD-9291 dimesylate
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.
-
BI-4020
BI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
-
Varlitinib
Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM respectively. Phase 2.
